ArticleBrain and behavior2026
Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionCognitive impairment is a common non-motor symptom of Parkinson's disease (PD) that markedly reduces patients' quality of life. Given the clinical heterogeneity of PD-related cognitive impairment (PDCI), further clarification of clinical and circulating biological factors associated with cognitive status may help improve our understanding of cognitive dysfunction in PD.
methodsIn this cross-sectional study, 243 patients with PD and 90 age- and sex-matched healthy controls (HCs) were enrolled. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and patients with PD were classified into the PD with cognitive impairment (PDCI) and PD without cognitive impairment (PDNCI) groups. Based on motor symptoms, PD patients were further divided into three subtypes: tremor-dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND). Group comparisons and logistic regression analyses were performed to examine factors associated with cognitive impairment.
resultsSerum irisin levels did not differ significantly between patients with PD and healthy controls (p = 0.478). Compared with PDNCI patients, those with PDCI had lower serum irisin levels. Among motor subtypes, the PIGD group showed a higher prevalence of cognitive impairment (68.8% vs. 46.2%, p < 0.001) and significantly lower irisin levels compared with the TD group [3.25 (2.62-4.14) vs. 4.12 (3.42-5.07) µg/mL, p < 0.001]. Serum irisin levels were weakly but positively associated with memory performance, and this association remained significant after FDR correction across the five cognitive domains (r = 0.194, FDR-adjusted p = 0.010). Compared with patients in the TD-high irisin group, those in the PIGD-low irisin group had higher odds of concurrent cognitive impairment (OR = 6.065, 95% CI: 2.974-18.638, p = 0.002).
conclusionCognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint-category analysis, patients in the PIGD-low-irisin group had higher odds of concurrent cognitive impairment than those in the TD-high-irisin group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.